Pharmaceutical - Respiratory and Pulmonary, Boehringer Ingelheim

Filter

Popular Filters

1 to 25 of 37 results

Boehringer Ingelheim enters research pact with Yale University

Boehringer Ingelheim enters research pact with Yale University

14-01-2015

German family-owned pharma major Boehringer Ingelheim has entered into a collaboration with Yale University,…

Boehringer IngelheimGermanyImmunologicalsOncologyPharmaceuticalResearchRespiratory and Pulmonary

More November EMA/CHMP recommendations

22-11-2014

A total of 10 new medicines have been recommended for approval at the November 2014 meeting of the European…

apremilastBoehringer IngelheimCelgene Corp.DermatologicalsEuropeNephrology and HepatologyNeurologicalnintedanibOfevOtezlaPharmaceuticalRasagilineRegulationRespiratory and PulmonarySanofiShionogiTeva Pharmaceutcal Industries

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

Boehringer Ingelheim's Spiriva Respimat NDA for asthma accepted for review by FDA

04-11-2014

German family-owned drug major Boehringer Ingelheim has had its Spiriva Respimat (tiotropium bromide)…

Boehringer IngelheimGermanyPharmaceuticalRegulationRespiratory and PulmonarySpirivaSpiriva Respimat

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

US FDA approves Genentech’s Esbriet and Boehringer Ingelheim’s Ofev for IPF

16-10-2014

The US Food and Drug Administration has approved Esbriet (pirfenidone), from Roche subsidiary Genentech,…

Boehringer IngelheimEsbrietGenentechnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

Boehringer Ingelheim invests 100 million euros to expanded Respimat production, as it's launched in UK

01-10-2014

German family-owned pharma major Boehringer Ingelheim is investing more than 100 million euros ($127…

Boehringer IngelheimGermanyMarkets & MarketingPharmaceuticalProductionRespimatRespiratory and PulmonarySpiriva RespimatUK

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

Boehringer’s Spiriva Respimat OKed by FDA for maintenance treatment of COPD

25-09-2014

German family-owned pharma major Boehringer Ingelheim Pharmaceuticals has received US Food and Drug Administration…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivaUSA

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

ERS 2014: Positive new data on Boehringer’s nintedanib in IPF patients

10-09-2014

A pre-specified subgroup analysis from the two replicate Phase III INPULSI trials, presented today at…

Boehringer IngelheimnintedanibPharmaceuticalResearchRespiratory and Pulmonary

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

Boehringer's tiotropium improves lung function in adolescent patients with symptomatic asthma

09-09-2014

German family-owned drug major Boehringer Ingelheim has reported Phase III trial results showing that…

AsthmaBoehringer IngelheimGermanyMajorPharmaceuticalPulmonologyResearchRespiratory and Pulmonarytiotropium

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

Asthma agents currently face a suboptimal coverage environment in Brazil and Mexico

21-08-2014

The asthma market in Brazil and Mexico currently faces severe coverage restrictions and, as the treatment…

Boehringer IngelheimBrazilGenentechMexicoNovartisPfizerPharmaceuticalRespiratory and PulmonarySpirivaXolair

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

FDA panel recommends Boehringer drug for the maintenance treatment of COPD

15-08-2014

There was good news late yesterday for German family-owned pharma major Boehringer Ingelheim, when an…

Boehringer IngelheimPharmaceuticalRegulationRespiratory and PulmonarySpirivatiotropiumUS Food and Drug AdministrationUSA

Global asthma market to hit $18 billion by 2021 boosted by biologics

Global asthma market to hit $18 billion by 2021 boosted by biologics

14-08-2014

The market for asthma drugs is predicted to reach $18 billion by 2021, according to new research from…

AdvairAsthmaAstraZenecaBoehringer IngelheimBreoGlaxoSmithKlineGlobalMarkets & MarketingNatasha SpillerPharmaceuticalRespiratory and PulmonaryRespiratory therapySpirivaSymbicort

Medivir licenses RSV program from Boehringer Ingelheim

Medivir licenses RSV program from Boehringer Ingelheim

05-08-2014

Swedish drugmaker Medivir has entered a license agreement with German family-owned pharma major Boehringer…

Boehringer IngelheimGlobalHuman respiratory syncytial virusLicensingMedivirMononegaviralesPharmaceuticalRespiratory and PulmonaryViral diseases

FDA approves Boehringer’s Striverdi Respimat for COPD

FDA approves Boehringer’s Striverdi Respimat for COPD

01-08-2014

The US Food and Drug Administration has approved German family-owned pharma major Boehringer Ingelheim’s…

Boehringer IngelheimPharmaceuticalPulmonologyRegulationRespiratory and PulmonaryStriverdi RespimatUSA

US breakthrough designation in IPF for Boehringer’s nintedanib

US breakthrough designation in IPF for Boehringer’s nintedanib

17-07-2014

The US Food and Drug Administration has granted Breakthrough Therapy designation for German family-owned…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

FDA accepts Boehringer’s nintedanib NDA; granted priority review for IPF

02-07-2014

The US subsidiary of German family-owned drug major Boehringer Ingelheim says that the New Drug Application…

Boehringer IngelheimnintedanibPharmaceuticalRegulationRespiratory and PulmonaryUSA

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

Boehringer submits tiotropium + olodaterol Respimat for European approval in COPD

02-07-2014

German family-owned pharma major Boehringer Ingelheim says it has submitted Marketing Authorization Applications…

Boehringer IngelheimEuropePharmaceuticalRegulationRespiratory and Pulmonarytiotropium + olodaterol Respimat

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

EMA accepts Boehringer’s accelerated marketing application for nintedanib in IPF

05-06-2014

German family-owned pharma major Boehringer Ingelheim said this morning that the European Medicines Agency…

Boehringer IngelheimEuropenintedanibPharmaceuticalRegulationRespiratory and Pulmonary

First Ph III data on Boehringer’s fixed-dose combo tiotropium plus olodaterol in COPD

22-05-2014

German family-owned drug major Boehringer Ingelheim has presented positive results of the VIVACITO (NCTO1559116)…

Boehringer IngelheimolodaterolPharmaceuticalResearchRespiratory and Pulmonarytiotropium

New Ph III data show tiotropium Respimat effective across asthma severities

03-03-2014

German family-owned drug major Boehringer Ingelheim has released new data from large scale, Phase III…

Boehringer IngelheimPharmaceuticalResearchRespimatRespiratory and Pulmonarytiotropium

Boehringer Ingelheim files for expanded EU indication for Respimat

Boehringer Ingelheim files for expanded EU indication for Respimat

13-11-2013

German independent drug major Boehringer Ingelheim has submitted an applications to extend the indication…

Boehringer IngelheimEuropePharmaceuticalRegulationRespimatRespiratory and PulmonarySpiriva

Generic risk to GSK's Advair prompts buy recommendation from analysts

10-09-2013

Pharmaceutical analysts are urging investors to buy shares of UK pharma major GlaxoSmithKline (LSE: GSK)…

AdvairAstraZenecaBoehringer IngelheimEuropeFinancialGlaxoSmithKlinePharmaceuticalRespiratory and PulmonarySandozSpirivaSymbicort

COPD trial shows comparable efficacy in Boehringer's Spiriva Respimat and HandiHaler

09-09-2013

One of largest chronic obstructive pulmonary disease (COPD) trials conducted to date confirms comparable…

Boehringer IngelheimEuropePharmaceuticalResearchRespiratory and PulmonarySpiriva

Novel LABA/LAMA products will capture greater market share than the LABA/ICS or LAMA drug classes by 2022

29-08-2013

The drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of…

AdvairAnoroBoehringer IngelheimGlaxoSmithKlineGlobalMarkets & MarketingPharmaceuticalRelvarRespiratory and PulmonarySpirivaTheravance

1 to 25 of 37 results

Back to top